LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced results from studies evaluating the Company’s lead drug candidate, ganetespib, a potent second-generation Hsp90 inhibitor, presented at the annual meeting of the American Society for Clinical Oncology (ASCO).
